Drug intelligence / Profile preview

PROSTYM

Development stage: Phase 4
Modality: Small Molecules
Administration: Oral

Overview

PROSTYM is an oral combination product consisting of bovine colostrum and Serenoa repens extracts. It is being investigated as a phytotherapy for the treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). The aim of its use is to enhance the quality of life and reduce pain symptoms in patients suffering from this condition.

Brand names: PROSTYM

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SRD5A1 (Steroid 5-alpha-reductase type 1)SRD5A2 (Steroid 5-alpha-reductase type II)

Beyond the preview

Go deeper on PROSTYM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROSTYM.

Explore the full profile